Ameriprise Financial Inc. increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 17.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 681,792 shares of the specialty pharmaceutical company’s stock after purchasing an additional 102,341 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.34% of Supernus Pharmaceuticals worth $27,271,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC grew its stake in Supernus Pharmaceuticals by 91.4% in the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 1,462 shares in the last quarter. Advisor Group Inc. grew its stake in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 410 shares in the last quarter. Victory Capital Management Inc. grew its stake in Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares in the last quarter. Finally, Flinton Capital Management LLC grew its stake in Supernus Pharmaceuticals by 88.9% in the second quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after purchasing an additional 2,240 shares in the last quarter. 98.34% of the stock is currently owned by institutional investors.

In other news, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction on Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the sale, the senior vice president now owns 12,500 shares of the company’s stock, valued at approximately $623,250. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at $36.45 on Thursday. The stock has a market capitalization of $1,901.82, a price-to-earnings ratio of 35.00, a price-to-earnings-growth ratio of 1.57 and a beta of 1.19. Supernus Pharmaceuticals, Inc. has a 52-week low of $21.60 and a 52-week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business’s revenue for the quarter was up 41.5% compared to the same quarter last year. equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.07 earnings per share for the current year.

SUPN has been the topic of several research analyst reports. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Piper Jaffray Companies reissued a “hold” rating and issued a $45.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Cantor Fitzgerald reissued a “buy” rating and issued a $49.00 price objective on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 19th. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price objective on the stock. in a research note on Tuesday, September 19th. They noted that the move was a valuation call. Finally, Janney Montgomery Scott reissued a “hold” rating and issued a $47.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $49.60.

TRADEMARK VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/12/07/supernus-pharmaceuticals-inc-supn-shares-bought-by-ameriprise-financial-inc.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.